Artelo Biosciences (ARTL) Expected to Announce Earnings on Monday

Artelo Biosciences (NASDAQ:ARTL) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect Artelo Biosciences to post earnings of ($0.13) per share for the quarter.

Artelo Biosciences (NASDAQ:ARTL) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.43). On average, analysts expect Artelo Biosciences to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Artelo Biosciences Price Performance

Artelo Biosciences stock opened at $1.02 on Friday. The firm has a market cap of $3.35 million, a price-to-earnings ratio of -0.36 and a beta of 1.03. The firm has a fifty day moving average price of $0.97 and a two-hundred day moving average price of $1.08. Artelo Biosciences has a fifty-two week low of $0.82 and a fifty-two week high of $1.59.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ARTL shares. D. Boral Capital reaffirmed a “buy” rating and issued a $6.00 target price on shares of Artelo Biosciences in a report on Monday, April 28th. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Artelo Biosciences in a research note on Tuesday, March 4th.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.